Single-use bioprocessing, often known as disposables, refers to a range of pharmaceutical products. And solutions intended to be used once before being thrown. Some of the most frequently used single-use bioprocessing products are media bags. Containers, filter assemblies, single-use bioreactors, disposable mixers, tubes, connections, and samplers. These goods are frequently used to manufacture monoclonal antibodies, vaccinations, the culture of plant cells, and certain cell therapies. They are also used by businesses that produce biopharmaceuticals. And work in the life sciences to boost output and facilitate disposal with little chance of cross-contamination.

The single-use bioprocessing market will grow rapidly, with a CAGR of 15.86%. From $14.83 billion in 2021 to $55.78 billion by 2030.

Market Dynamics


A major factor boosting market expansion is the rising global demand for pharmaceutical products. While manufacturing pharmaceuticals, single-use bioprocessing technology is often use in media preparation and shipment of biologics. Furthermore, there is a rising desire for single-use items made from high-grade polymer materials. & plastic composites since they provide increased inherent strength while lowering total operational expenses. It also promotes consistency in biomanufacturing, which contributes to market growth.


Both the creation of bioprocesses and the manufacturing of biopharmaceuticals have heavily embraced single-use technologies in recent years. Despite the fact that the benefits of these technologies are widely recognize, there are significant concerns over extractables and leachables that originate from single-use systems because of the potential harm they may do to the health of patients and the quality of the products. It’s crucial to comprehend how disposable technologies will impact the reliability. And security of pharmaceutical items before incorporating them into manufacturing.


China, followed by India, is a high-potential market in the Asia-Pacific area for single-use bioprocessing systems. This is attributable to favorable government support, increased private investment, a growing senior population. A considerable increase in the trend to outsource to emerging Asian markets. And the availability of a skilled workforce in these countries. According to a National Bureau of Statistics analysis, China’s entire R&D. Investment in 2021 will be at 2.79 trillion yuan (about $441.13 billion), rising 14.2% yearly.

Market Segmentation

By Product, Due to ongoing improvements in these goods. And the rising importance of bioprocessing operations in the manufacturing process, the simple & peripheral elements category recorded the highest share of more than 48.85% of the total revenue in 2021. Tubing, filters, and connectors ruled the simple & peripheral elements segment. And transfer systems since most single-use vendors offer tubing. And connections in a format compatible with single-use bags, bioreactors. Or other single-use bioprocessing equipment.

By Workflow, In 2021, the upstream bioprocessing segment. Accounted for the greatest portion of the total revenue share, more than 57.60%. This is due to the ongoing improvements and advances in upstream bioprocessing technology. For instance, cutting-edge technologies like the Ambr 15 micro-bioreactor system from Sartorius. AG offer automated experimental setup and sampling in addition to high-throughput upstream. Process development, efficient cell culture processing, and media & feed optimization. These options are expect to accelerate segment growth and shorten the time require for upstream bioprocessing processes.

By End-user, In 2021, the biopharmaceutical manufacturers market segment ruled the market with the largest share of more than 58.10%. The segment has experienced rapid expansion due to rising contract manufacturing and research services. As well as an increase in the commercial success of biologics in recent years. In bioprocessing operations, CROs and CMOs can provide a number of advantages, including scalability, flexibility. A reduction in the need for internal infrastructure, and dedicated supply channels.

Regional Insights

More than 33.00% of global revenue was generate in North America in 2021 due to the region’s establish pharmaceutical and biomanufacturing sector and extensive R&D efforts. Similar to this, a growing emphasis on vaccine production drives. The need for single-use bioprocessing equipment to support local efforts at disease prevention. Additionally, the Bio-process System Alliance (BPSApresence )’s in North America. Which promotes the use of single-use technology, will significantly boost the region’s disposable system sales.

Over the forecast period, Asia Pacific will develop at the fastest CAGR. Multiple investments from numerous international corporations have been made in the region’s expand bioprocessing market.

Key Players 

  • Danaher Corporation
  • Merck KGaA
  • Sartorius Stedim Biotech S.A. 
  • Avantor
  • Thermo Fisher Scientific
  • Corning
  • Entegris
  • Getinge AB
  • Eppendorf AG
  • CESCO Bioengineering Co. Ltd.
  • Cellexus
  • ABEC, Inc.
  • Able Corporation & Biott Corporation
  • PBS Biotech, Inc.
  • Distek, Inc.
  • G&G Technologies
  • Solida Biotech GmbH
  • Celltainer Biotech
  • Meissner Filtration Products, Inc.
  • Bbi-biotech GmbH
  • OmniBRx Biotechnologies
  • Satake Chemical Equipment Mfg., Ltd.
  • Stobbe Pharma GmbH
  • Pierre Guerin
  • Catalent
  • Kuhner AG

The single-use bioprocessing industry will grow rapidly, with a CAGR of 15.86%. From $14.83 billion in 2021 to $55.78 billion by 2030. The biopharmaceutical industry’s expanding need heavily influences the market for single-use bioprocessing. Because single-use bioprocessing systems boost process efficiency and lower the expenses associated with sterilizing, cleaning. And maintaining steel bioreactors, most biopharmaceutical businesses are increasingly implementing this technology.

Leave a Reply

Your email address will not be published. Required fields are marked *